Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are...
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 10:33:48 24 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 10:33:50 24 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/24/2009 10:36:08 AM

RSS FEED

» Help

Current DateTime: 10:33:50 24 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size

Pfizer's Viagra
AP
Pfizer's Viagra

Times may be tough, but apparently not tough enough--at least, not yet--for American men to sacrifice their virility.

A few months ago, during the last earnings season, I put forth an anecdotal theory (see links below) that the weak economy may be leading to flacid sales of the expensive pills for erectile dysfunction (ED). But this earnings season's results show that impotence drug sales may be more resilient than I thought.

Earlier this week Pfizer [PFE  Loading...      ()   ]reported that Viagra sales went up 13 percent from the third quarter of last year to the third quarter of this year. Not only that, but U.S. revenue from the little blue pill climbed sequentially (from the second quarter of this year to the third quarter) from $199 million to $236 million. That's not all new business, much of the increase probably comes from a price increase, but even that flies in the face of a report in "The New York Times"  yesterday about people giving up or cutting back on their meds in this economy. Even though docs and the companies will tell you impotence could be a symptom of serious medical problems, ED drugs are considered so-called lifestyle, elective products. So, the fact that guys are paying even more for them these days may say something.

Then, this morning Eli Lilly [LLY  Loading...      ()   ]reported that U.S. revenue from Cialis jumped 20 percent quarter over quarter. And they rose $12 million sequentially. Here, too, on the conference call officials acknowledged most of that comes from a price hike and not so much from more demand. They also said Cialis' market share inched up 1.4 percent in the quarter in part due to the recent launch of a one-a-day version of the drug. And for those who think direct-to-consumer advertising doesn't work, LLY said since it started running commercials for one-a-day Cialis that its market share bumped up another .06 percent. Even sales of little Levitra co-owned by GlaxoSmithKline[GSK  Loading...      ()   ], Schering-Plough [SGP  Loading...      ()   ]and Bayer [BAY  Loading...      ()   ]crept up ever so slightly. Maybe it's all part of the whole cocooning, stay-at-home, go out less thing.

Viva Viagra, indeed.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 05:23:04 24 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 09:37:23 24 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 10:17:33 24 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 07:49:43 24 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters